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Survival rates of children with cancer have strongly improved during the past decades, but much of this improvement has been
disclosed with substantial delay by traditional methods of survival analysis, which reflect survival experience of patients diagnosed
many years ago. In this paper, the use of a new method of survival analysis, denoted period analysis, for providing more up-to-date
estimates of 10-year survival curves of children with cancer is empirically evaluated using data of the Surveillance, Epidemiology, and
End Results Program of the United States National Cancer Institute. It is shown that period analysis provides much more up-to-date
estimates of survival curves than traditional cohort-based survival analysis indeed, at least as long as there is ongoing improvement in
survival rates over time, as it seems to be the case for many forms of childhood cancer. The most recent 10-year period survival
estimates indicate that survival rates of children with cancer achieved by the end of the 20th century are substantially higher than
previously available survival statistics have suggested. Application of period analysis may be particularly useful in the field of childhood
cancer as it may help to prevent patients, their families and clinicians from being burdened by outdated, often too pessimistic survival
expectations.
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Although childhood cancer is rare, accounting for about 1% of all
cancer cases only (Little, 1999), the associated burden for the
patients and their families is immense. Fortunately, prognosis for
children with cancer has greatly improved over the past decades,
principally owing to more effective chemotherapy (La Vecchia et al,
1998; Ries et al, 1999).
The most commonly reported measures of prognosis of children
with cancer are 5-year survival rates (e.g. Gatta et al, 2002).
Although most deaths among children with cancer occur during
the first 5 years following diagnosis, the proportion of late deaths
occurring beyond the fifth year following diagnosis is not
negligible for many forms of childhood cancers (Mertens et al,
2001; Mo ¨ller et al, 2001). Therefore, more long-term survival
statistics are of particular interest for childhood cancer.
However, traditional estimates of long-term survival rates
(Cutler and Ederer, 1958; Kaplan and Meier, 1958), which pertain
to cohorts of patients diagnosed many years ago, may be overly
pessimistic in case of recent improvements in prognosis. A few
years ago, a new method of survival analysis, denoted period
analysis, has been introduced to provide more up-to-date
estimates of long-term survival rates (Brenner and Gefeller, 1996,
1997). For adulthood cancers, performance of period analysis has
meanwhile undergone extensive empirical evaluation, which
demonstrated that this method provides much more up-to-date
estimates of long-term survival rates than the traditional methods
of survival analysis indeed (Brenner and Hakulinen, 2002a,b,c;
Brenner et al, 2002b). However, no systematic evaluation has been
carried out for childhood cancers, and, with few exceptions
(Brenner et al, 2001; Burkhardt-Hammer et al, 2002), the method
has not been used for monitoring progress in childhood cancer so
far.
The aim of this analysis was to provide an empirical evaluation
of the performance of period analysis for deriving up-to-date
estimates of 10-year survival curves of children with cancer.
MATERIALS AND METHODS
All data presented in this paper are derived from the 1973–1999
public use database of the Surveillance, Epidemiology, and End
Results (SEER) Program (2002) of the United States National
Cancer Institute. Although the SEER Program is not a true
nationwide population-based cancer registry scheme, it is the most
authoritative source of information on cancer incidence and
survival in the US, and it is considered as the standard for quality
among cancer registries around the world. Quality control has
been an integral part of SEER since its inception. Every year,
studies are conducted in the SEER areas to evaluate the quality and
completeness of the data being reported (SEER’s standard for case
ascertainment is 98%).
Data included in the 1973–1999 SEER database are from
population-based cancer registries in Connecticut, New Mexico,
Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San
Francisco-Oakland, which together cover a population of about 24
million people. In this analysis, patients with a first diagnosis of
cancer below age 15 years between 1975 and 1999, who have been
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yfollowed for vital status until the end of 1999 are included. Patients
with missing information on month or year of diagnosis (0.3%) or
survival time (0.6%) were excluded, as were patients whose cancer
was reported by death certificate only (0.2%) or autopsy only
(0.4%). Data are presented for all races and both sexes combined.
Specific analyses are shown for various age groups (0–4, 5–9,
10–14 years) and the four most common diagnostic groups
according to the International Classification of Childhood Cancer:
leukaemias, lymphomas, central nervous system and miscella-
neous intracranial and intraspinal neoplasms, and sympathetic
nervous system tumours. The focus of this analysis is on 10-year
survival rates rather than the more commonly reported 5-year
survival rates.
The principle of period analysis has been described in detail
elsewhere (Brenner and Gefeller, 1996, 1997). Briefly, period
estimates of survival for a recent time period are obtained by left
truncation of observations at the beginning of that period in
addition to right censoring at its end. The approach used for the
empirical evaluation is illustrated in Figure 1: 10-year survival
curves actually observed for children diagnosed with cancer
between 1985 and 1989 (the most recent cohort of children for
whom 10-year follow-up was complete at the time of this analysis,
solid grey frame in Figure 1) are compared with the most up-to-
date estimates of 10-year survival curves that might have been
available in 1985–1989 (i.e. at the time of diagnosis of these
children) using either period analysis or traditional cohort
analysis. For simplicity, any delay in cancer registration, mortality
follow-up, and data analysis are neglected. The 10-year survival
curves available in 1985–1989 by traditional cohort analysis would
have pertained to survival experience in 1975–1989 of patients
diagnosed in 1975–1979 (solid black frame). By contrast, 10-year
survival curves obtained by period analysis would have exclusively
reflected survival experience in 1985–1989. This analysis would
have included patients diagnosed in 1975–1989, but all observa-
tions would have been left truncated at the beginning of 1985 and
right censored at the end of 1989 (dashed black frame). With that
approach, survival experience during the first year following
diagnosis is provided by patients diagnosed between 1984 and
1989, survival experience in the second year following diagnosis is
provided by patients diagnosed between 1983 and 1988 and so on,
until survival experience during the 10th year after diagnosis,
which is provided by patients diagnosed between 1975 and 1980.
In addition, analogously derived 10-year period survival curves for
the most recent period (1995–1999) for which data were available at
the time of this analysis are also given (black squares frame).
All analyses were performed with the SAS software package
using a publicly available macro for both cohort and period
analysis, which is described in detail elsewhere (Brenner et al,
2002a). Since mortality from competing causes of death is almost
negligible for children, and relative survival rates are essentially
the same as absolute survival rates for this age group, only absolute
survival rates are presented in this paper. Standard errors of
survival rates were calculated according to Greenwood’s (1926)
method.
Years of follow-up 
Years of 
diagnosis  1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 
1975  1  1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10  10 
1976    1  1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10  10 
1977      1  1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10  10 
1978        1  1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10  10 
1979          1  1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10  10 
1980       1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1981        1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1982         1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1983           1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10   
1984            1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1985             1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1986              1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1987               1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1988                1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1989                 1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10  10 
1990                  1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9  9/10 
1991                   1  1/2  2/3  3/4  4/5  5/6  6/7  7/8  8/9 
1992                    1  1/2  2/3  3/4  4/5  5/6  6/7  7/8 
1993                     1  1/2  2/3  3/4  4/5  5/6  6/7 
1994                      1  1/2  2/3  3/4  4/5  5/6 
1995                       1  1/2  2/3  3/4  4/5 
1996                        1  1/2  2/3  3/4 
1997                         1  1/2  2/3 
1998                          1  1/2 
1999                           1 
Figure 1 Database for the 10-year survival curves actually observed for patients diagnosed in 1985–1989 (solid grey frame), and for the most up-to-date
estimates of 10-year survival curves available in 1985–1989 by period analysis (dashed black frame) or cohort analysis (solid black frame). The black squares
frame indicates the database for the most up-to-date period estimates of 10-year survival curves available in 1995–1999. The numbers within the cells
indicate the years of follow-up since diagnosis.
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Table 1 shows the numbers of children, by age and diagnostic
groups, who were included in this analysis. Overall, 18100 children
were included. Almost half of the children were less than 5 years old
at the time of diagnosis, about a quarter of the children were in each
of the other two age groups (5–9 and 10–14 years). The most
common diagnostic group was leukaemia, which accounted for 31%
of all childhood neoplasms (acute lymphocytic leukaemia: 24%,
other leukaemia: 7%), followed by central nervous system
neoplasms (overall: 21%, astrocytoma: 10%, primitive neuroecto-
dermal tumours: 5%, others: 6%), lymphomas (overall: 10%,
Hodgkin’s lymphoma: 4%, other lymphomas: 6%), and sympathetic
nervous system tumours (8%). The latter group overwhelmingly
consists of neuroblastomas and ganglioneuroblastomas (7.8%).
Each of the four diagnostic groups specifically addressed in this
analysis included more than 1400 children.
Figure 2 shows the observed 10-year survival curves of children
diagnosed with any form of cancer at various ages in 1985–1989
(grey lines) compared with the most up-to-date survival curves
available in 1985–1989 by period analysis (dashed black lines) and
cohort analysis (solid black lines). Overall, and within each single
age group, the 10-year survival curves available by period analysis
in 1985–1989 would have come much closer to the 10-year survival
curves later observed for patients diagnosed in that time period
than the corresponding 10-year survival curves available by cohort
analysis. Whereas cohort estimates of 10-year survival available in
1985–1989 would have been between 10.2 and 13.5 percent units
lower than the 10-year survival rates later observed for children
diagnosed in that period, the discrepancy would have been
between 0.6 and 3.5 percent units only for the period estimates.
Nevertheless, even the period estimates tended to be lower than the
10-year survival rates later observed for newly diagnosed patients
in all cases.
The increase in 10-year survival between patients diagnosed in
1975–1979 and 1985–1989 was particularly strong for children
with leukaemias and lymphomas (þ18.9 and þ18.7 percent units,
respectively) (see Figure 3, upper two graphs). Accordingly,
children diagnosed with these neoplasms in the late 1980s were
confronted with much too pessimistic 10-year survival statistics
obtained by traditional cohort analysis, which equal the 10-year
survival rates of patients diagnosed 10 years earlier. Period
estimates of 10-year survival that could have been derived in
1985–1989 would also have been somewhat too pessimistic, but
much less so than the traditional cohort estimates. Despite
differences in absolute levels of survival rates, this pattern was
seen in additional analyses for each of the major subgroups (acute
lymphocytic leukaemia, other leukaemias, Hodgkin’s lymphoma,
and other lymphomas; data not shown).
For children diagnosed with neoplasms of the central and
sympathetic nervous system in 1985–1989, 10-year survival rates
were somewhat lower (below 60%) (see Figure 3, lower two
graphs). The latest cohort estimates of 10-year survival available at
the time of their diagnosis would again have been somewhat too
pessimistic, although the differences were not as large as for the
other diagnostic groups. On the other hand, the latest period
estimates available in those years would almost perfectly have
predicted the 10-year survival curves observed 10 years later for
these children. Additional analysis revealed that this was true for
each of the major subgroups (astrocytoma, primitive neuroecto-
dermal tumours, other central nervous system tumours, neuro-
blastoma, and ganglioneuroblastoma) within these diagnostic
groups (data not shown).
Of course, it would be of great interest to know the 10-year
survival rates to be expected by children diagnosed in more recent
years. A definitive answer to this question will only be available 10
years from now. However, the empirical evaluation described
above suggests that the period estimates of 10-year survival curves
for the 1995–1999 period, which are depicted by black squares in
Figures 2 and 3, do come quite close to the 10-year survival curves
of patients diagnosed in that period. Although these survival
curves may actually still be too pessimistic, they suggest that there
has been substantial further recent improvement in survival rates
in all age groups and for all diagnostic groups considered in this
analysis. The 1995–1999 period estimate of 10-year survival for all
ages and all forms of childhood cancer combined is 75.2%, 8.7
percent units higher than the 10-year survival rate for the 1985–
1989 cohort (grey solid curve), which is the latest cohort estimate
that can be derived from the current data base.
In Figures 2 and 3, only point estimates of survival rates are
shown. Of course, it is also important to take their standard errors
into account. Standard errors were generally of similar magnitude
for period and cohort estimates. The standard errors for the
different 10-year survival rates ranged from 0.7 to 0.9% for all
cancers combined, from 1.1 to 1.4, 1.4 to 1.7, and 1.4 to 1.7% for
age groups 0–4, 5–9 and 10–14 years, respectively, and from 1.3
to 1.7, 2.0 to 2.6, 1.7 to 2.0, and 2.8 to 3.2% for leukaemias,
lymphomas, central and sympathetic nervous system neoplasms,
respectively.
DISCUSSION
To my knowledge, this is the first systematic evaluation of the use
of period analysis for deriving up-to-date long-term survival
curves of children with cancer. It could be shown that period
analysis provides much more up-to-date estimates of survival
curves than traditional cohort-based survival analysis indeed, at
least as long as there is ongoing improvement in survival rates over
time, as it seems to be the case for each of the most common forms
of childhood cancer. These results are consistent with the results of
previous empirical evaluations of the method’s performance in the
analysis of cancer survival among adults (Brenner and Hakulinen,
2002a,b,c; Brenner et al, 2002b). However, because improvement
in prognosis has been stronger for most childhood cancers than
for cancers among adults, the advantage of period analysis over
traditional survival analysis with respect to derivation of up-to-
date survival rates appears to be even larger for childhood cancer.
Despite being more up-to-date than the traditional cohort-based
survival curves, even the period survival curves tended to be
somewhat too pessimistic in all cases (albeit much less so than the
traditional cohort-based survival curves). As expected from theory,
this particularly applied to those neoplasms for which the most
rapid increase in survival rates was observed (Brenner and
Gefeller, 1996, 1997), namely leukaemias and lymphomas. In
theory, period estimates of long-term survival curves may also
Table 1 Number of children diagnosed with cancer below age 15 years
between 1975 and 1999 included in this analysis
Overall 18100 (100.0%)
By age at diagnosis (years)
0–4 8018 (44.3%)
5–9 5029 (27.8%)
10–14 5053 (27.9%)
By the most common diagnostic groups
Leukaemias 5664 (31.3%)
Lymphomas 1825 (10.1%)
Central nervous system and
miscellaneous intracranial and intraspinal
neoplasms
3776 (20.9%)
Sympathetic nervous system
tumours
1449 (8.0%)
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detection or therapy do not increase chances of cure, but merely
postpone cancer deaths. In fact, this theoretical possibility has
been repeatedly forwarded as a caveat against the use of period
analysis, and it has been suggested to be of particular concern for
childhood cancers, as a consequence of possible late adverse
treatment effects. However, studies have shown that modern
treatment of childhood cancers tended to reduce rather than
increase occurrence of late cancer deaths (in addition to reducing
occurrence of early cancer deaths) (Robertson et al, 1994; Hudson
et al, 1997; Mo ¨ller et al, 2001). In agreement with these findings,
our empirical evaluation suggests that the theoretical possibility of
overoptimistic survival estimates by period analysis appears to be
as irrelevant in practice as it is for adulthood cancers (Brenner and
Hakulinen, 2002a,b,c; Brenner et al, 2002b). In the contrary, the
issue to be concerned about is that even the most up-to-date
period estimates of long-term cancer patient survival available at a
given time are usually too pessimistic if there is ongoing
improvement in prognosis (as it seems to be the case for most
childhood cancers). Therefore, even the most up-to-date period
estimates should usually be regarded as conservative (possibly too
low) estimates of long-term survival rates achieved at a given time
period and to be expected by newly diagnosed patients in that
period.
In the interpretation of the results, the following limitations
should be kept in mind. Although, overall, a very large number of
children were included in this analysis, sample size limitations
hindered a more detailed analysis for the less common diagnostic
groups or for single forms of childhood cancer. Restriction of
separate analyses to the most common diagnostic groups, along
with presentation of results by 5-year calendar intervals rather
than single calendar years ensured that the largest standard error
for any of the presented 10-year survival estimates was below 3.3%
in all cases, and within the range from 1 to 2.5% for the majority of
the presented 10-year survival estimates. There is also no obvious
reason, why the performance of period analysis should be different
for those diagnostic groups for which no separate analysis was
carried out because of sample size limitations. An additional
analysis for all those diagnostic groups combined yielded the same
overall patterns for the performance of period analysis compared
to cohort analysis illustrated for the more common diagnostic
groups in this paper (data not shown).
Although this paper addressed 10-year survival rates rather than
the more commonly reported 5-year survival rates, even longer-
term survival rates, such as 20- or 30-year survival rates would be
of interest for children with cancer, given that the occurrence of
late deaths is not negligible for these children, and given the much
longer life expectancy children with cancer would have in the
absence of cancer compared to adult cancer patients. However, an
empirical evaluation of the performance of period analysis for such
long-term survival rates would require much longer time series of
cancer registration than the 27-year time series meanwhile
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Figure 2 Observed 10-year survival curves of children diagnosed with
any form of cancer at various ages in 1985–1989 (grey lines) compared
with the most up-to-date survival curves available in 1985–1989 by period
analysis (dashed black lines) and cohort analysis (solid black lines). The black
squares indicate the period survival curves for the 1995–1999 period.
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Figure 3 Observed 10-year survival curves of children diagnosed with
various forms of cancer in 1985–1989 (grey lines) compared with the most
up-to-date survival curves available in 1985–1989 by period analysis
(dashed black lines) and cohort analysis (solid black lines). The black
squares indicate the period survival curves for the 1995–1999 period.
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evaluations have been carried out using the almost 50-years-long
time series of the Finnish Cancer Registry. These analyses
suggested, that the advantage of period analysis over traditional
survival analysis for deriving up-to-date survival estimates is even
larger for these longer-term survival rates (Brenner and Hakulinen,
2002c).
Presentation of results in this paper focused on comparison of
results obtained by period analysis with those obtained by
frequently used cohort analysis, in which only patients who have
been under examination for the entire follow-up interval of
interest are included. Other conventional analyses have also
included patients who were not seen for the entire follow-up
interval of interest and whose survival time was censored at the
closing date of follow-up (unless they died or were lost before that
date) (e.g. Stiller and Eatcock, 1994, 1999; Mott, 1995). Additional
analysis of survival rates by the so-called ‘complete analysis’
(including all patients diagnosed prior to the closing date of
follow-up, see Brenner and Gefeller, 1997) confirmed previous
observations (Brenner and Hakulinen, 2002a; Brenner et al, 2002b)
that, although this type of analysis provides more up-to-date
(and precise) long-term survival estimates than conventional
cohort analysis, these estimates are, nevertheless, still much less
up-to-date than those obtained by period analysis (data not
shown).
In conclusion, this empirical evaluation suggests that the period
analysis approach, which has long been used in other fields of
sciences, such as demography, is at least as useful for deriving
more up-to-date estimates of long-term survival for childhood
cancer as it is for adulthood cancers. The 10-year period survival
estimates for the 1995–1999 period also indicate that survival rates
of children with cancer achieved by the end of the 20th century are
higher than previously available survival statistics have suggested.
For example, the 10-year survival period estimate for the 1995–
1999 period for all forms of cancer combined (75%) is even higher
than the recently published cohort estimate of 5-year survival
of 70% (pertaining to the 1985–1989 cohort of children in the
same data base) (Gatta et al, 2002). Application of period analysis
may be particularly useful in the field of childhood cancer as it
may help to prevent patients, their families and clinicians from
being burdened by outdated, often too pessimistic survival
expectations.
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